The future of cancer care is personalisation. New breakthroughs are increasingly highly targeted, with powerful results, but only for patients with particular genetic markers.
Last weekend, I travelled to Chicago for the annual conference of the American Society of Clinical Oncologists— the annual event where major breakthroughs in cancer care are announced.
Just about everyone seems to agree that the runaway success story of ASCO this year is AstraZeneca, with plenary sessions for the sixth year in a row and